Ocular CDO sells 2,810 shares in tax trade

Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,810 shares of common stock at a weighted average price of $8.28 per share.

Rhea-AI Filing Summary

Ocular Therapeutix Chief Development Officer Peter Kaiser reported an open-market sale of 2,810 shares of common stock at a weighted average price of $8.28 per share. The shares were sold under a durable automatic sale instruction to cover tax withholding from restricted stock units vesting on February 22, 2026. After this transaction, he directly owns 269,108 shares.

Insider Trade Summary

Net Seller: 2,810 shares

Net Sell 1 txn

Insider Kaiser Peter

Role Chief Development Officer

Sold 2,810 shs ($23K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,810	$8.28	$23K

Holdings After Transaction: Common Stock — 269,108 shares (Direct)

Footnotes (2)

1. F1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2300 to $8.3600, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Peter Kaiser report at OCUL?

Peter Kaiser reported an open-market sale of 2,810 shares of Ocular Therapeutix common stock. The sale was executed under a durable automatic instruction and was tied to tax withholding obligations from restricted stock units vesting on February 22, 2026.

How many Ocular Therapeutix (OCUL) shares did Peter Kaiser sell?

Peter Kaiser sold 2,810 shares of Ocular Therapeutix common stock. This transaction was disclosed as an open-market sale and related to a sell-to-cover election for tax withholding on vested restricted stock units under a pre-established automatic instruction.

At what price were the OCUL shares sold by Peter Kaiser?

The reported weighted average sale price was $8.28 per share. According to the disclosure, the shares were sold in multiple trades at prices ranging from $8.23 to $8.36, and detailed price breakdowns are available on request from the company or regulators.

Why did Peter Kaiser sell OCUL shares in this Form 4 filing?

The sale was made to satisfy tax withholding obligations connected with the vesting of restricted stock units on February 22, 2026. It followed a durable automatic sale instruction adopted on April 9, 2024, and was not described as a discretionary trade.

How many OCUL shares does Peter Kaiser own after the reported sale?

After the transaction, Peter Kaiser directly owns 269,108 shares of Ocular Therapeutix common stock. This figure reflects his holdings immediately following the 2,810-share open-market sale executed under the automatic tax-related instruction described in the disclosure.

Was the OCUL share sale by Peter Kaiser discretionary?

The disclosure states the sales do not represent a discretionary trade by Peter Kaiser. They were executed under a durable automatic sale instruction adopted on April 9, 2024, specifically to implement a sell-to-cover election for RSU-related tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 06:19 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaiser Peter

(Last) (First) (Middle)

C/O OCULAR THERAPEUTIX, INC.

15 CROSBY DRIVE

(Street)

BEDFORD MA 01730

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OCULAR THERAPEUTIX, INC [ OCUL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		S(1)		2,810(1)	D	$8.28(2)	269,108	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Ocular Therapeutix, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on April 9, 2024, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations in connection with the vesting of restricted stock units on February 22, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.2300 to $8.3600, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Todd Anderman, Attorney-in-Fact for Peter Kaiser	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.